|
News For PFE;BMY From The Last 14 Days Check below for free stories on PFE;BMY the last two weeks. |
|
|
| June 18, 2013 |
| 09:38 EDT |  | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM |
|
| June 17, 2013 |
| 16:00 EDT | | PFE | Options Update; June 17, 2013
 Subscribe for More Information |
|
| 08:36 EDT |  | PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. |
|
| 07:28 EDT |  | PFE, BMY | Cambridge Healthtech Institute to host a conference
Subscribe for More Information |
|
| June 14, 2013 |
| 16:00 EDT | | PFE | Options Update; June 14, 2013
Subscribe for More Information |
|
| 09:03 EDT | | BMY | Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions
AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. |
|
| 08:02 EDT | | BMY | Bristol-Myers, Simcere enter Orencia pact for China
Subscribe for More Information |
|
| 06:45 EDT | | PFE | Zoetis volatility elevated into Pfizer split-off
Subscribe for More Information |
|
| June 13, 2013 |
| 16:00 EDT | | PFE | Options Update; June 13, 2013
Subscribe for More Information |
|
| 11:02 EDT | | BMY | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information |
| |
| 07:32 EDT | | PFE | European League Against Rheumatism to host annual meeting
Subscribe for More Information |
|
| June 12, 2013 |
| 16:02 EDT | | PFE | Options Update; June 12, 2013
Subscribe for More Information |
|
| 13:31 EDT | | PFE | Mylan could be interested in generic assets split from Pfizer, Bloomberg says
|
|
| 13:15 EDT | | BMY | Bristol-Myers, AstraZeneca issue statement on review of some therapies
Subscribe for More Information |
|
| 08:28 EDT | | PFE | Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer wins $2.15B settlement from Teva and Sun for patent infringement
Subscribe for More Information |
|
| June 11, 2013 |
| 18:09 EDT | | BMY | Orencia trial data shows efficacy rate comparable to Humira
Bristol-Myers announced the results of year two data from AMPLE, a trial of 646 patients comparing the subcutaneous formulation of Orencia, or abatacept, vs. Humira, or adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism annual congress and highlighted during a congress press conference. AMPLE met its primary endpoint as measured by non-inferiority of ACR20 at year one. The Orenica regimen achieved comparable rates of efficacy vs. the Humira regimen, or 64.8% vs. 63.4%, respectively. Onset of response was also generally similar for the two groups. Year two of the study remained investigator-blinded. At year two, the Orencia regimen achieved the same rate of efficacy as the Humira regimen based on ACR20. |
|
| 16:00 EDT | | PFE | Options Update; June 11, 2013
Subscribe for More Information |
|
| 15:15 EDT | | PFE | Pfizer June volatility at one-year high
Subscribe for More Information |
|
| 08:01 EDT | | BMY | Leerink's major pharma and biotech analysts hold a conference call
Subscribe for More Information |
| |
|
|
|
|
